Fig. 7: Assessment of in vivo IL-12 mRNA immunotherapy. | Nature Communications

Fig. 7: Assessment of in vivo IL-12 mRNA immunotherapy.

From: Synthesis of ionizable lipopolymers using split-Ugi reaction for pulmonary delivery of various size RNAs and gene editing

Fig. 7

a Structure of IL-12 mRNA and protein; b Experimental scheme of treatment (https://BioRender.com/o56i111); c Serum IL-12p70 concentration 24 h post 1st and 2nd i.v. injections of IL-12 mRNA and mCherry RNA (5 ug dose per mouse), normal saline (NS). Data are presented as Means ± SD (n = 5 biological replicates), (unpaired t test, two-tailed, **p < 0.005, ***p < 0.0005); d Representative images of bioluminescence in lungs upon time; e Representative images of ex vivo lungs; f Kaplan–Meier survival analysis comparing overall survival (OS) between control (NS, n  =  4 biological replicates), mCherry RNA (U155@lipids mCherry RNA, n = 4 biological replicates), and IL-12-mRNA treated (U155@lipids IL-12 mRNA, n  =  5 biological replicates). P-values were calculated using log-rank test; g Days survival past in vivo bioluminescence signal reached 2 × 105 p/sec/cm2/sr. n = 4 for NS and mCherry RNA, n = 5 for IL-12 mRNA, unpaired t test, two-tailed, **p = 0.0072 and 0.0032. Source data are provided as a Source Data file.

Back to article page